Navigation Links
Drug-Coated Stent

A new study shows drug-emitting stents are effective at keeping arteries open in even the most complex of patients. Researchers looked at stents coated with the drug sirolimus. It is an immunosuppressive agent. The goal when used in heart patients is to prevent the artery from closing again.//

Stents are used to prop open an artery and doctors say they have been very useful. However, in 30 percent of patients with diabetes, small coronary blood vessels, and long lesions, the area that was treated closes up again. For the last 20 years, doctors have been working to devise medications to prevent the problem from recurring. This new study looked at a drug-coated stent in patients with more challenging cardiac problems.

The study, included 53 medical centers in the United States. More than 1,000 patients received either a sirolimus-coated stent or a standard stent. The researchers report the rate of the artery re-closing with the use of the sirolimus stent was reduced from 21 percent to 8.5 percent.

Researchers say, "In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect." Both future blockages and other medical problems were avoided. Investigators suggest the results show both improved effectiveness and safety and perhaps they will alter the future of coronary treatments.
'"/>




Page: 1

Related medicine news :

1. Failure of Drug-Coated Stent
2. Stronger Backing for Drug-Coated Stents
3. Drug-Coated Stents – Proven to be More Effectiv
4. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
5. Stent shows promise in keeping arteries open
6. Failure of Drug-Coated Stent
7. Stronger Backing for Drug-Coated Stents
8. Drug-Coated Stents – Proven to be More Effectiv
9. Stent Effective In Keeping Arteries Open
10. The Efficacy Of Newer Stents Questioned
11. Analyzing The Side Effects Of Sirolimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... Guide ...      , No matter on which side of the Atlantic devicemakers do ... device regulations they have to follow. , In addition to the full text of ...
(Date:6/28/2017)... ... , ... Anyone with a remote control has seen the never-ending twists on the house flipping ... get rich in no time. But what about the buyers of the flipper's flip. ... of a flipped house. An email recently sent to Gary Case said, “Just closed ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold & ... for the Illinois State Bar Association , in accordance with the organization’s rules of ... following a state-wide election and served in that capacity for the past year prior to ...
(Date:6/28/2017)... ... , ... American Farmer proudly announces the participation of Pure Line Seeds, Inc ... to broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... seed. As demand grew, the small company located in Moscow, Idaho extended its sales ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: